In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 44 for your search:
Drug:  exemestane
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 40 to 70
Sponsor: NIGMS
Protocol IDs: 0412-14, UO1-GM61373-06, NCT00228956

2.

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 09 SEIN 09, NCT01127295

3.

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11SEIN12, NCT01612871

4.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: Postmenopausal
Sponsor: Other
Protocol IDs: TENBC, NCT01648608

5.

Phase: Phase III
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: CDR0000635986, COL-MNEMOSYNE, 2007-12, INCA-RECF0899, EUDRACT-2008-003620-32, MNEMOSYNE, NCT00893061

6.

Phase: Phase III
Type: Treatment
Status: Active
Age: Postmenopausal
Sponsor: Other
Protocol IDs: SHBCC0701, NCT00902954

7.

Phase: Phase III
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02623, CDR0000692475, SWOG-S1007, S1007, U10CA180888, U10CA032102, NCT01272037

8.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: DETECT III, 2010-024238-46, NCT01619111

9.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: GBG 54, 2009-015122-11, NCT01638247

10.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UNIRAD, 2012-003187-44, UC-0140/1208, NCT01805271

11.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GEICAM/2013-02, 2013-003170-27, NCT02028507

12.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: D2610C00003, 2010-021220-10, NCT01202591

13.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LCCC 2010-535, NCT01484041

14.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 25 and over
Sponsor: Other
Protocol IDs: C/23/2011, 2011-000454-32, NCT01791985

15.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLEE011X2106, NCT01857193

16.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C31001, NCT02049957

17.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000595712, SINGAPORE-NCC0706, NCC0706, NCT00687648

18.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IRB00012969, WCI1534-08, NCT00941330

19.

Phase: Phase II
Type: Treatment
Status: Active
Age: 50 to 80
Sponsor: Other
Protocol IDs: CH-BC-011, NCT01431053

20.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011-1239, NCT01627067

21.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Fudan BR2012-12, NCT01654185

22.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001Y24135, 2012-003065-17, NCT01698918

23.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 02112, NCT01594216

24.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001Y2201, NCT01783444

25.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Metronomic Therapy, NCT01924078
1   
New Search